2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

By T. Smith, H. Ozer, L. Miller, C. Schiffer, R. Winn, James R. Anderson, P. N. Anderson, J. Armitage, S. Beckhardt, C. Bennett and 15 more. Journal of Clinical Oncology, 2000

936 citations recorded by the source corpus.

Subfields: Hematology, Neurology, Oncology

View Paper: https://www.semanticscholar.org/paper/c221c1906c1eba6f56024304812b65f46c3c130e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Crawford
2. Henry F. Chambers
3. D. Dale
4. Sherwood L. Gorbach
5. A. Bisno
6. Edward L. Kaplan
7. E. J. Goldstein
8. Dennis L. Stevens

Citations in the corpus

• Chemotherapy‐induced neutropenia (2004, background): “In addition, the clinical evidence supports recognizing the elderly as one of the special populations for which the guidelines of the American Society of Clinical Oncology (ASCO) suggest considering primary prophylaxis with growth factors in conjunction with myelosuppressive chemotherapy.(15,16) Ano”
• Practice guidelines for the diagnosis and management of skin and soft-tissue infections. (2005, background): “The importance of treatment with adjunct growth factor or granulocyte transfusion is unsubstantiated, but they are frequently considered for patients who remain profoundly neutropenic and unresponsive to antimicrobial therapy [177].”